Pipeline. Advanced medicines that demonstrate both strong clinical performance and benefits to patients.

AbbVie Pipeline Update. February 9, 2023. Page 2. 2. AbbVie R&D Pipeline. □ CUG-252* (IL-2 Mutein) SLE. □ CLF065* (GLP-2 agonist) IBD. □ ABBV-151 (GARP+ ...

ABBV-101 is a small molecule BTK degrader that is being investigated to treat B-cell malignancies.

2 февр. 2022 г. · AbbVie Inc. is revving its engines with a deep pipeline of late-stage drug programs focused on immunology and cancer.

5 февр. 2024 г. · AbbVie's oncology pipeline could do with a boost: its late-stage highlights consist largely of new uses for approved products, as well as the ...

28 мая 2024 г. · By utilizing these biomarkers as targets, ADCs are designed to deliver potent cancer cell death-inducing agents called 'payloads' to the tumor.

2 авг. 2024 г. · AbbVie gains Cerevel's clinical-stage assets that complement AbbVie's emerging neuroscience pipeline as well as branded products for treating psychiatric ...

1 сент. 2023 г. · Here's an overview of AbbVie's pipeline, indicating the number of drugs in different phases of development until August 30, 2023.

24 июл. 2023 г. · The first patient has been dosed in the Phase 3 Step-Up HS study evaluating upadacitinib (RINVOQ) in adults and adolescents with moderate to severe ...

18 окт. 2023 г. · The best news includes CD20×CD3 bispecific antibody Epcoritamab getting approval, as well as daily dose formulation of JAK1 inhibitor Upadacitinib being ...